In response to the European Union legislative changes on trimethylbenzoyl diphenylphosphine oxide (TPO) and growing consumer concerns, Dymax expanded its portfolio of TPO-free formulations designed to meet evolving safety standards and support long-term product design and planning.

Dymax reports that the TPO-free products have been rigorously tested to deliver the performance and quality characteristics expected of all Dymax chemistries. For medical device applications, adhesives meet biocompatibility standards, including ISO 10993-5 cytotoxicity and others as appropriate, helping support internal validation or documentation requirements. Additionally, manufacturers who want to integrate the formulations into existing production environments can seek assistance from Dymax technical service specialists who can help customers move confidently through validation processes with current applications or new product development efforts.

Recognizing that any formulation change can raise questions, Dymax provides technical and regulatory support to help customers assess and adopt TPO-free options, including current application product review to determine potential TPO-containing product use, product data sheets for material property review prior to in-house validation, application engineering guidance to evaluate any required process adjustments, and access to regulatory teams for questions about global compliance requirements.

Learn more at dymax.com.